JP2021505661A - アスパラギナーゼを用いた治療法 - Google Patents

アスパラギナーゼを用いた治療法 Download PDF

Info

Publication number
JP2021505661A
JP2021505661A JP2020548883A JP2020548883A JP2021505661A JP 2021505661 A JP2021505661 A JP 2021505661A JP 2020548883 A JP2020548883 A JP 2020548883A JP 2020548883 A JP2020548883 A JP 2020548883A JP 2021505661 A JP2021505661 A JP 2021505661A
Authority
JP
Japan
Prior art keywords
asparaginase
complex
peg
protein
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020548883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505661A5 (https=
Inventor
パイン，ポリー
グルサハニ，ヘママリニ
Original Assignee
ジャズ ファーマシューティカルズ アイルランド リミテッド
ジャズ ファーマシューティカルズ アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャズ ファーマシューティカルズ アイルランド リミテッド, ジャズ ファーマシューティカルズ アイルランド リミテッド filed Critical ジャズ ファーマシューティカルズ アイルランド リミテッド
Publication of JP2021505661A publication Critical patent/JP2021505661A/ja
Publication of JP2021505661A5 publication Critical patent/JP2021505661A5/ja
Priority to JP2024023383A priority Critical patent/JP2024069234A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020548883A 2017-11-30 2018-11-30 アスパラギナーゼを用いた治療法 Pending JP2021505661A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024023383A JP2024069234A (ja) 2017-11-30 2024-02-20 アスパラギナーゼを用いた治療法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762592982P 2017-11-30 2017-11-30
US62/592,982 2017-11-30
US201862625078P 2018-02-01 2018-02-01
US62/625,078 2018-02-01
US201862631142P 2018-02-15 2018-02-15
US62/631,142 2018-02-15
US201862673075P 2018-05-17 2018-05-17
US62/673,075 2018-05-17
PCT/US2018/063448 WO2019109018A1 (en) 2017-11-30 2018-11-30 Methods of treatment with asparaginase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024023383A Division JP2024069234A (ja) 2017-11-30 2024-02-20 アスパラギナーゼを用いた治療法

Publications (2)

Publication Number Publication Date
JP2021505661A true JP2021505661A (ja) 2021-02-18
JP2021505661A5 JP2021505661A5 (https=) 2022-01-04

Family

ID=66664263

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548883A Pending JP2021505661A (ja) 2017-11-30 2018-11-30 アスパラギナーゼを用いた治療法
JP2024023383A Pending JP2024069234A (ja) 2017-11-30 2024-02-20 アスパラギナーゼを用いた治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024023383A Pending JP2024069234A (ja) 2017-11-30 2024-02-20 アスパラギナーゼを用いた治療法

Country Status (12)

Country Link
US (1) US20230173042A1 (https=)
EP (1) EP3716997A4 (https=)
JP (2) JP2021505661A (https=)
KR (2) KR20200119234A (https=)
CN (1) CN111818937A (https=)
AU (2) AU2018375183B2 (https=)
BR (1) BR112020010976A2 (https=)
CA (2) CA3083499C (https=)
IL (1) IL274865B2 (https=)
MX (1) MX2020005567A (https=)
SG (1) SG11202004965RA (https=)
WO (1) WO2019109018A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024515555A (ja) * 2021-04-06 2024-04-10 ジャズ ファーマシューティカルズ アイルランド リミテッド Ｌ－アスパラギナーゼの製剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
GB201912020D0 (en) * 2019-08-21 2019-10-02 Porton Biopharma Ltd Therapeutic Conjugate
JP2022553399A (ja) * 2019-10-25 2022-12-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 組換えｌ－アスパラギナーゼ
WO2022211829A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2024015529A2 (en) 2022-07-14 2024-01-18 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311233A1 (en) * 2006-03-03 2009-12-17 Lorenzi Philip L Materials and methods directed to asparagine synthetase and asparaginase therapies
JP2012532185A (ja) * 2009-07-06 2012-12-13 アリゼ ファーマ トゥー ペグ化されたｌ−アスパラギナーゼ
JP2015510918A (ja) * 2012-03-21 2015-04-13 エリテック・ファルマ 急性骨髄性白血病（ａｍｌ）の処置のための薬剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044360A2 (en) * 2000-11-28 2002-06-06 Phoenix Pharmacologics, Inc. Modified arginine deiminase
CN1360049A (zh) * 2000-12-20 2002-07-24 上海博德基因开发有限公司 一种新的多肽——人l－天冬酰胺酶24.53和编码这种多肽的多核苷酸
ITMI20060612A1 (it) * 2006-03-30 2007-09-30 Keryos Spa New activaded poly-ethylene glycols-and related polymers and their applications
CN105802948B (zh) * 2014-12-29 2020-06-09 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用
CN105802946B (zh) * 2014-12-29 2025-08-22 江苏众红生物工程创药研究院有限公司 聚乙二醇化的门冬酰胺酶及其应用
EP3535386A4 (en) * 2016-11-04 2020-04-15 Georgia State University Research Foundation, Inc. ENDOTOXIN-FREE ASPARAGINASE
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311233A1 (en) * 2006-03-03 2009-12-17 Lorenzi Philip L Materials and methods directed to asparagine synthetase and asparaginase therapies
JP2012532185A (ja) * 2009-07-06 2012-12-13 アリゼ ファーマ トゥー ペグ化されたｌ−アスパラギナーゼ
JP2015510918A (ja) * 2012-03-21 2015-04-13 エリテック・ファルマ 急性骨髄性白血病（ａｍｌ）の処置のための薬剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNALS OF SURGICALONCOLOGY, vol. 23, JPN6023043508, 2016, pages 849 - 855, ISSN: 0005177981 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024515555A (ja) * 2021-04-06 2024-04-10 ジャズ ファーマシューティカルズ アイルランド リミテッド Ｌ－アスパラギナーゼの製剤

Also Published As

Publication number Publication date
IL274865B1 (en) 2025-04-01
KR20250086810A (ko) 2025-06-13
IL274865B2 (en) 2025-08-01
CA3240356A1 (en) 2019-06-06
US20230173042A1 (en) 2023-06-08
MX2020005567A (es) 2020-08-20
IL274865A (en) 2020-07-30
AU2018375183A1 (en) 2020-06-25
CN111818937A (zh) 2020-10-23
SG11202004965RA (en) 2020-06-29
AU2018375183B2 (en) 2024-09-26
WO2019109018A1 (en) 2019-06-06
CA3083499C (en) 2024-10-01
BR112020010976A2 (pt) 2020-11-17
CA3083499A1 (en) 2019-06-06
EP3716997A1 (en) 2020-10-07
EP3716997A4 (en) 2022-02-23
JP2024069234A (ja) 2024-05-21
KR20200119234A (ko) 2020-10-19
AU2024278286A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
JP2021505661A (ja) アスパラギナーゼを用いた治療法
JP6014956B2 (ja) ペグ化されたｌ−アスパラギナーゼ
JP5746137B2 (ja) アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用
JP6243452B2 (ja) アルブミン結合アルギニンデイミナーゼ融合たんぱく質を含有する医薬組成物
JP6961061B2 (ja) 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼ
EP2799540A1 (en) Human arginase and pegylated human arginase and application thereof
JP6382934B2 (ja) 癌治療のためのａｄｉ−ｐｅｇ２０抗体に対して低減された交差反応性を有するアルギニンデイミナーゼ
RS57077B2 (sr) Pegilovana l-asparaginaza
Zhang et al. PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida
HK40040856A (en) Methods of treatment with asparaginase
HK1173092B (en) Pegylated l-asparaginase
Simay Production, characterization, and biological impacts of recombinant L-glutaminase on leukemia
HK40075284A (zh) 用於癌症治疗的对adi-peg20抗体具有降低的交叉反应性的精氨酸脱亚氨酶
Chung Development and rational design of enzymes for enhanced performance
JP2026506061A (ja) アルギニンデイミナーゼ変異体、共有結合二量体及びその複合体並びに使用
TW201634058A (zh) 工程化之嵌合聚乙二醇化ａｄｉ及使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231020